Targeting LRH‑1 in hepatoblastoma cell lines causes decreased proliferation

Jin,Jingling; Jin,Junliang; Woodfield,Sarah   E.; Patel,Roma   H.; Jin,Nan   Ge; Shi,Yan; Liu,Bin; Sun,Wenjing; Chen,Xiangmei; Yu,Yang; Vasudevan,Sanjeev   A.

doi:10.3892/or.2018.6793

Targeting LRH‑1 in hepatoblastoma cell lines causes decreased proliferation

Authors:
- Jingling Jin
- Junliang Jin
- Sarah E. Woodfield
- Roma H. Patel
- Nan Ge Jin
- Yan Shi
- Bin Liu
- Wenjing Sun
- Xiangmei Chen
- Yang Yu
- Sanjeev A. Vasudevan
View Affiliations

Affiliations: Divisions of Pediatric Surgery and Surgical Research, Michael E. DeBakey, Department of Surgery, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA, Carnegie Vanguard High School, Houston, TX 77019, USA, Ruiz Department of Ophthalmology and Visual Science, University of Texas Health Science Center at Houston, Houston, TX 77030, USA, Department of Pediatrics‑Oncology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA, Department of Microbiology & Infectious Disease Center, School of Basic Medical Science, Peking University Health Science Center, Beijing 100191, P.R. China
Published online on: October 15, 2018 https://doi.org/10.3892/or.2018.6793
Pages: 143-153
Copyright: © Jin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatoblastoma is the most common malignant liver tumor in children. Since it is often unresectable and exhibits drug resistance, the treatment of advanced hepatoblastoma is challenging. The orphan nuclear receptor liver receptor homolog‑1 (LRH‑1) serves prominent roles in malignancy; however, to the best of our knowledge, the role of LRH‑1 in hepatoblastoma remains unknown. In the present study, human hepatoblastoma cell lines were analyzed; the mRNA and protein expression levels of LRH‑1 were significantly higher in HepG2 and HuH6 cells compared with those in HepT1 cells and control THLE‑2 cells. Knockdown of LRH‑1 resulted in decreased HepG2 and HuH6 cell proliferation via downregulation of cyclin D1 (CCND1) and c‑Myc. Furthermore, treatment with an LRH‑1 antagonist (LRA) inhibited the proliferation and colony formation of cell lines in a dose‑dependent manner, and induced cell cycle arrest at G1 phase through inhibition of CCND1 expression. Finally, LRA treatment enhanced the cytotoxic effects of doxorubicin on hepatoblastoma cells. Collectively, these findings suggested that LRH‑1 may have an important role in the progression of hepatoblastoma and implicated LRA as a novel, potential therapeutic agent for the treatment of hepatoblastoma.

View Figures

View References

1	Buendia MA: Unravelling the genetics of hepatoblastoma: Few mutations, what else? J Hepatol. 6:1202–4. 2014. View Article : Google Scholar
2	von Schweinitz D: Hepatoblastoma: Recent developments in research and treatment. Semin Pediatr Surg. 21:21–30. 2012. View Article : Google Scholar : PubMed/NCBI
3	von Schweinitz D: Management of liver tumors in childhood. Semin Pediatr Surg. 15:17–24. 2006. View Article : Google Scholar : PubMed/NCBI
4	Schmid I, Haberle B, Albert MH, Corbacioglu S, Fröhlich B, Graf N, Kammer B, Kontny U, Leuschner I, Scheel-Walter HG, et al: Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer. 58:539–544. 2012. View Article : Google Scholar : PubMed/NCBI
5	Malogolowkin MH, Katzenstein HM, Krailo M, Chen Z, Quinn JJ, Reynolds M and Ortega JA: Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. J Clin Oncol. 26:2379–2383. 2008. View Article : Google Scholar : PubMed/NCBI
6	Warmann SW, Armeanu S, Frank H, Buck H, Graepler F, Lemken ML, Heitmann H, Seitz G, Lauer UM, Bitzer M and Fuchs J: In vitro gene targeting in human hepatoblastoma. Pediatr Surg Int. 22:16–23. 2006. View Article : Google Scholar : PubMed/NCBI
7	Warmann S, Hunger M, Teichmann B, Flemming P, Gratz KF and Fuchs J: The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: Clinical course and in vivo model. Cancer. 95:1795–1801. 2002. View Article : Google Scholar : PubMed/NCBI
8	Fayard E, Auwerx J and Schoonjans K: LR H-1 An orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends Cell Biol. 14:250–260. 2004. View Article : Google Scholar : PubMed/NCBI
9	Fayard E, Schoonjans K, Annicotte JS and Auwerx J: Liver receptor homolog 1 controls the expression of carboxyl ester lipase. J Biol Chem. 278:35725–35731. 2003. View Article : Google Scholar : PubMed/NCBI
10	Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, Arslan AA, Bueno-de-Mesquita HB, Gallinger S, Gross M, et al: A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 42:224–228. 2010. View Article : Google Scholar : PubMed/NCBI
11	Annicotte JS, Fayard E, Swift GH, Selander L, Edlund H, Tanaka T, Kodama T, Schoonjans K and Auwerx J: Pancreatic-duodenal homeobox 1 regulates expression of liver receptor homolog 1 during pancreas development. Mol Cell Biol. 23:6713–6724. 2003. View Article : Google Scholar : PubMed/NCBI
12	Thiruchelvam PT, Lai CF, Hua H, Thomas RS, Hurtado A, Hudson W, Bayly AR, Kyle FJ, Periyasamy M and Photiou A: The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells. Breast Cancer Res Treat. 127:385–396. 2011. View Article : Google Scholar : PubMed/NCBI
13	Bolado-Carrancio A, Riancho JA, Sainz J and Rodriguez-Rey JC: Activation of nuclear receptor NR5A2 increases Glut4 expression and glucose metabolism in muscle cells. Biochem Biophys Res Commun. 446:614–619. 2014. View Article : Google Scholar : PubMed/NCBI
14	Lin Q, Aihara A, Chung W, Li Y, Huang Z, Chen X, Weng S, Carlson RI, Wands JR and Dong X: LRH1 as a driving factor in pancreatic cancer growth. Cancer Lett. 345:85–90. 2014. View Article : Google Scholar : PubMed/NCBI
15	Botrugno OA, Fayard E, Annicotte JS, Haby C, Brennan T, Wendling O, Tanaka T, Kodama T, Thomas W, Auwerx J and Schoonjans K: Synergy between LRH-1 and beta-catenin induces G1 cyclin-mediated cell proliferation. Mol Cell. 15:499–509. 2004. View Article : Google Scholar : PubMed/NCBI
16	Dube C, Bergeron F, Vaillant MJ, Robert NM, Brousseau C and Tremblay JJ: The nuclear receptors SF1 and LRH1 are expressed in endometrial cancer cells and regulate steroidogenic gene transcription by cooperating with AP-1 factors. Cancer Lett. 275:127–138. 2009. View Article : Google Scholar : PubMed/NCBI
17	Whitby RJ, Stec J, Blind RD, Dixon S, Leesnitzer LM, Orband-Miller LA, Williams SP, Willson TM, Xu R, Zuercher WJ, et al: Small molecule agonists of the orphan nuclear receptors steroidogenic factor-1 (SF-1, NR5A1) and liver receptor homologue-1 (LRH-1, NR5A2). J Med Chem. 54:2266–2281. 2011. View Article : Google Scholar : PubMed/NCBI
18	Whitby RJ, Dixon S, Maloney PR, Delerive P, Goodwin BJ, Parks DJ and Willson TM: Identification of small molecule agonists of the orphan nuclear receptors liver receptor homolog-1 and steroidogenic factor-1. J Med Chem. 49:6652–6655. 2006. View Article : Google Scholar : PubMed/NCBI
19	Corzo CA, Mari Y, Chang MR, Khan T, Kuruvilla D, Nuhant P, Kumar N, West GM, Duckett DR, Roush WR and Griffin PR: Antiproliferation activity of a small molecule repressor of liver receptor homolog 1. Mol Pharmacol. 87:296–304. 2015. View Article : Google Scholar : PubMed/NCBI
20	Benod C, Carlsson J, Uthayaruban R, Hwang P, Irwin JJ, Doak AK, Shoichet BK, Sablin EP and Fletterick RJ: Structure-based discovery of antagonists of nuclear receptor LRH-1. J Biol Chem. 288:19830–19844. 2013. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Woodfield SE, Shi Y, Patel RH, Jin J, Major A, Sarabia SF, Starosolski Z, Zorman B, Gupta SS, Chen Z, et al: A novel cell line based orthotopic xenograft mouse model that recapitulates human hepatoblastoma. Sci Rep. 7:177512017. View Article : Google Scholar : PubMed/NCBI
23	Heng JC, Feng B, Han J, Jiang J, Kraus P, Ng JH, Orlov YL, Huss M, Yang L, Lufkin T, et al: The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. Cell Stem Cell. 6:167–174. 2010. View Article : Google Scholar : PubMed/NCBI
24	Wagner RT, Xu X, Yi F, Merrill BJ and Cooney AJ: Canonical Wnt/beta-catenin regulation of liver receptor homolog-1 mediates pluripotency gene expression. Stem Cells. 28:1794–1804. 2010. View Article : Google Scholar : PubMed/NCBI
25	Pelengaris S, Khan M and Evan G: c-MYC: More than just a matter of life and death. Nat Rev Cancer. 2:764–776. 2002. View Article : Google Scholar : PubMed/NCBI
26	Annicotte JS, Chavey C, Servant N, Teyssier J, Bardin A, Licznar A, Badia E, Pujol P, Vignon F, Maudelonde T, et al: The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene. Oncogene. 24:8167–8175. 2005. View Article : Google Scholar : PubMed/NCBI
27	Bertolin K, Gossen J, Schoonjans K and Murphy BD: The orphan nuclear receptor Nr5a2 is essential for luteinization in the female mouse ovary. Endocrinology. 155:1931–1943. 2014. View Article : Google Scholar : PubMed/NCBI
28	Bayrer JR, Mukkamala S, Sablin EP, Webb P and Fletterick RJ: Silencing LRH-1 in colon cancer cell lines impairs proliferation and alters gene expression programs. Proc Natl Acad Sci USA. 112:2467–2472. 2015. View Article : Google Scholar : PubMed/NCBI
29	Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK and von Schweinitz D: Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest. 74:809–818. 1996.PubMed/NCBI